Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Other Non-Commercial Sponsor
National Cancer Institute (NCI)
This trial has a single cohort that will go through two phases. Participants will first be treated with chemoradiotherapy. In this phase, they will receive veliparib (orally, twice daily) and will undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity. Participants will then be treated with maintenance chemotherapy. This phase will begin 4 weeks after the chemoradiotherapy phase, and participants will receive veliparib (orally, twice daily) and temozolomide (orally, once daily) on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.